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“Education is the best provision for old age.”
—Aristotle (1)
ajor advances in the treatment of acute and chronic
oronary heart disease (CHD) have occurred during the last
alf-century. An analysis of the Framingham Heart Study
howed a 59% decrease in death rates from CHD between
950 and 1999 (2) and, in just the last 2 decades alone,
ge-adjusted death rates for men and women in the U.S.
ave declined 43% (3). This profound decrease in CHD
ortality has been fueled by substantial decreases in the
revalence of major cardiovascular risk factors (notably,
igarette smoking, elevated blood cholesterol, hypertension)
See page 1247
nd the dramatic evolution of evidence-based therapies
including antiplatelet agents, beta-blockers, angiotensin-
onverting enzyme inhibitors [ACEI], statins, and myocar-
ial revascularization). Ford et al. (3) estimated that 90%
f the clinical event rate reduction in CHD mortality during
he last 2 decades of the 20th century was attributable to
eductions in major risk factors and to the more widespread
tilization of evidence-based medical therapies (3). Al-
hough there has likewise been a dramatic evolution in
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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os/Abbott Laboratories and PDL Biopharma.yocardial revascularization (notably percutaneous coro-
ary intervention [PCI]), only about 5% of the decline in
HD mortality between 1980 and 2000 in patients with
hronic angina could be attributed to revascularization
rocedures (3).
Against this backdrop of clear clinical benefits from
vidence-based medical practice, significant challenges re-
ain in translating important results of randomized clinical
rials, observational studies, registries, and epidemiological
urveys into actual clinical practice. Indeed, a compelling
ationale for formulating clinical practice guidelines, an
mportant activity that represents one of the most meaning-
ul missions of professional societies such as the American
ollege of Cardiology (ACC) and the American Heart
ssociation (AHA), is to provide physicians with evidence-
ased treatment recommendations and best practices to
nhance clinical outcomes and reduce care variations—
specially in high-risk patients who might be expected to
erive the most clinical benefit.
The elderly are a high-risk group subject to a “treatment-
isk paradox”: they tend to receive paradoxically less aggres-
ive evidence-based secondary prevention than younger,
ower risk patients (4). Current ACC/AHA clinical practice
uidelines for the treatment of acute coronary syndromes
ACS) do not alter therapeutic recommendations based on
ge, apart from encouraging appropriate risk stratification,
ttention to comorbidities, and appropriate dosing of med-
cations in elderly patients (5,6). However, on the basis of
egistry data obtained from the large CRUSADE national
uality improvement initiative, Alexander et al. (7) demon-
trated that the use of many recommended therapies in the
lderly was significantly lower than in younger patients.
mong 56,963 non–ST-segment elevation ACS patients in
hat registry whose in-hospital care was assessed with
CC/AHA clinical practice guidelines, 58% were 65
ears, 35% were75 years, and 11% were85 years of age.
fter adjustment for age-related differences in treatments
nd outcomes and after controlling for contraindications
nd comorbidities, elderly patients with ACS were signifi-
antly less likely to receive acute antiplatelet and antithrom-
in therapy within the first 24 h, less likely to undergo early
atheterization or revascularization, and less likely to receive
lopidogrel and statins at hospital discharge. Importantly,
lthough in-hospital mortality and complication rates in-
reased with advancing age, patients 65 years of age who
eceived more ACC/AHA guideline-recommended thera-
ies had lower in-hospital mortality even after adjustment
han those who did not (7). Similar data from GRACE
Global Registry of Acute Coronary Events), another large
nternational registry of patients with ACS with or without
T-segment elevation, reported significantly decreased use
f recommended therapies in the elderly (8). Thus, concor-
ant findings from 2 ACS registries emphasize that even
hort-term outcomes in the elderly may be favorably im-
p
t
i
o
t
m
e
3
m
P
a
o
s
m
a
u
b
c
p
m
w
p
t
a
a
i
w
g
b
p
n
i
e
h
i
h
o
m
r
t
l
“
m
c
p
a
v
v
d
s
m
C
(
(
g
C
t
p
a
a
2
t
c
f
t
p
w
s
c
m
b
I
u
w
s
p
p
s
m
5
w
T
a
i
c
t
m
t
a
e
s
b
i
M
f
(
l
s
l
i
s
s
p
t
1256 Boden and Maron JACC Vol. 51, No. 13, 2008
Editorial Comment April 1, 2008:1255–7acted by more widespread use of proven secondary preven-
ion therapies. Little evidence, however, is available regard-
ng the potential long-term benefits associated with the use
f evidence-based medical therapies in the elderly.
In this issue of the Journal, Setoguchi et al. (9) studied
emporal trends in mortality after hospitalization for acute
yocardial infarction (MI) in 21,484 community-dwelling
lderly patients (average age 80 years) who survived at least
0 days after discharge, by using data derived from phar-
acy assistance programs and Medicare in New Jersey and
ennsylvania between 1995 and 2004. They found that after
djusting for patient demographics, comorbidities, duration
f the MI hospitalization, patterns of previous health
ervices use, and clustering of patients within hospitals,
ortality after MI decreased significantly over time, by
pproximately 3% per year. After further adjustment for the
se of statins, beta-blockers, ACEI, angiotensin receptor
lockers, and antiplatelet drugs over time in this elderly
ohort, the 10-year time trend in post-MI mortality im-
rovement was completely abolished, indicating that the
ore favorable outcome in long-term mortality post-MI
as likely due to the increased use of proven secondary
revention medications after discharge. In addition, al-
hough there was evidence that MI-related PCI procedures
lso may have contributed to improved survival, after
djusting for MI-related PCI procedural use during the
ndex MI hospitalization, the temporal change associated
ith improved prognosis was largely attenuated. This sug-
ests that improvement in short-term outcomes may have
een attributable to PCI, whereas evidence-based secondary
revention therapies provided significant long-term prog-
ostic benefit.
What do these data add to what we know about the
mportance of optimal medical therapy in reducing clinical
vents in patients with CHD? Several observational studies
ave shown improved survival after hospitalization for MI
n the last 30 years (10–16), and clearly these improvements
ave been multifactorial, owing to more sensitive methods
f detecting MI, coronary care units with arrhythmia
onitoring, the advent of mechanical and pharmacologic
eperfusion, and the expanding use of multiple medications
hat have been shown in placebo-controlled trials to reduce
ong-term mortality. More recently, data from randomized
strategy trials” comparing multifaceted, aggressive (opti-
al) medical therapy with PCI in both ACS (17,18) and
hronic stable angina patients (19) have underscored the
ower and promise of secondary prevention as a proven
pproach to reduce major cardiovascular events. The pro-
ocative finding by Setoguchi et al. (9) extends the obser-
ation of Ford et al. (3) that the largest contributor to the
ecrease in CHD mortality is the use of evidence-based
econdary prevention, and underscores the value of optimal
edical therapy as was used in the ICTUS (Invasive Versus
onservative Treatment in Unstable Coronary Syndromes)17), OAT (Occluded Artery Trial) (18), and COURAGE pClinical Outcomes Utilizing Revascularization and Ag-
ressive Drug Evaluation) (19) trials.
Additionally, as was observed in both the OAT and
OURAGE trials, there were no differences in the overall
rial primary end points for the prespecified subset of
atients 65 years compared with patients 65 years of
ge. In COURAGE, 40% of patients were 65 years of
ge, and in this age group the rate of death or MI during a
.5- to 7-year follow-up was no greater in those randomized
o an initial strategy of optimal medical therapy alone
ompared with optimal medical therapy plus PCI. The data
rom Setoguchi et al. (9) support the value of medical
herapy in a large cohort of community-dwelling elderly
atients whose mean age was 80 years and of whom 73%
ere women.
Nevertheless, there are certain limitations of the present
tudy. The study population was derived from medical
laims data of Medicare beneficiaries in 2 states and thus
ay not be generalizable to MI patients comprising a
roader geographic and demographic distribution. A single
nternational Classification of Diseases, revision 9, code was
sed to identify patients who were hospitalized for MI,
hich may include an unknown percentage of patients with
mall, incidental MI. Inclusion in the trial was restricted to
atients who had been active participants in their insurance
rograms for at least 1 year before the index MI and who
urvived the first 30 days after the index MI discharge,
eaning that most patients were likely censored for at least
weeks after their acute MI—a high-risk period associated
ith increased mortality, especially in the elderly (20,21).
he use of antiplatelet and antithrombin therapy was not
scertained in the present analysis, nor was the possibly
mportant contribution of lifestyle interventions (diet, exer-
ise, weight control, and smoking cessation). Furthermore,
he persistence of medication use after discharge was not
easured.
In summary, the findings from the present study, al-
hough largely circumstantial, are nevertheless compelling
nd consistent with a large and expanding body of scientific
vidence that has validated the importance of established
econdary prevention therapies (aspirin, clopidogrel, statins,
eta-blockers, ACEI/angiotensin receptor blockers—alone or
n combination) in reducing long-term death and recurrent
I in CHD patients. In light of the fact that CHD is
undamentally a systemic disease with focal manifestations
acute plaque rupture triggering clinical events), it is both
ogical and intuitive that the use of antiatherothrombotic
trategies would hold the greatest promise for achieving
ong-term clinical event reduction. It is particularly gratify-
ng to see new evidence that the mortality benefit of
econdary prevention extends to elderly patients. This
hould motivate clinicians to avoid the “treatment-risk
aradox” and to apply evidence-based preventive interven-
ions as readily and intensively in high-risk elderly CHD
atients as in younger CHD patients at lower risk.
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